Characteristics of α 1 ‐adrenoceptor antagonists‐induced ejaculatory dysfunction on spontaneous seminal emission in rats
Basic & Clinical Pharmacology & Toxicology · 2024
DOI: 10.1111/bcpt.13993 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2024. Verfasst von Masaru Yoshizumi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Physiology and Anatomy, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan. Hauptthemen laut MEDLINE: Adrenergic alpha-1 Receptor Antagonists, Ejaculatory Dysfunction, Naphthalenes, Piperazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: JSPS KAKENHI, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Although α 1 ‐adrenoceptor (α 1 ‐AR) antagonists used to treat benign prostatic hyperplasia can cause ejaculation disorders, the aetiology of this adverse event is still controversial. Therefore, we investigated the effects of antagonists with different affinities for α 1 ‐AR subtypes on ejaculatory function and their mechanisms of action in normal rats. In the spontaneous seminal emission (SSE) test, systemically administered prazosin, terazosin, tamsulosin and naftopidil decreased the weight of ejaculated seminal material in a dose‐dependent manner; the potency order was as follows: tamsulosin > terazosin > prazosin > naftopidil. The selective α 1D ‐AR antagonist BMY7378 had no effect on SSE. Intrathecal tamsulosin and naftopidil did not inhibit SSE. Tamsulosin, the most potent, was ineffective as a single dose and significantly increased seminal vesicle fluid in rats treated for 2 weeks but did not significantly change retrograde ejaculation. These results indicated that the difference in inhibitory potency of the five α 1 ‐AR antagonists against SSE was due to the involvement of α 1A ‐AR subtypes. Our results further suggested that α 1 ‐AR antagonist‐induced ejaculatory dysfunction at the peripheral level was mainly due to the loss of seminal emission, although some retrograde ejaculation may also be involved.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Physiology and Anatomy, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
- Division of Pharmaceutical Center, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
ORCID-Profile: Masaru Yoshizumi
Förderung
- JSPS KAKENHI
- Japan Society for the Promotion of Science
Zitieren
APA
Yoshizumi, M., Ise, S. N., Yonezawa, A., Watanabe, C., Sakurada, S., & Mizoguchi, H. (2024). Characteristics of α 1 ‐adrenoceptor antagonists‐induced ejaculatory dysfunction on spontaneous seminal emission in rats. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13993
Vancouver
Yoshizumi M, Ise SN, Yonezawa A, Watanabe C, Sakurada S, Mizoguchi H. Characteristics of α 1 ‐adrenoceptor antagonists‐induced ejaculatory dysfunction on spontaneous seminal emission in rats. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.13993
BibTeX
@article{Yoshizumi2024,
author = {Yoshizumi, Masaru and Ise, Shin-Nosuke and Yonezawa, Akihiko and Watanabe, Chizuko and Sakurada, Shinobu and Mizoguchi, Hirokazu},
title = {Characteristics of α 1 ‐adrenoceptor antagonists‐induced ejaculatory dysfunction on spontaneous seminal emission in rats},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2024},
doi = {10.1111/bcpt.13993}
}
EUVIMED